Advertisement

Topics

Sucampo Pharmaceuticals, Inc. and Takeda Company Profile

06:14 EDT 23rd June 2018 | BioPortfolio

Sucampo Pharmaceuticals, Inc., an international pharmaceutical company, is focused on the discovery, development and commercialization of proprietary drugs based on prostones. The therapeutic potential of prostones, which occur naturally in the human body as a result of enzymatic (15-PGDH) transformation of certain fatty acids, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' Chairman and Chief Executive Officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding Chief Executive Officer and currently Advisor, International Business Development, and a member of the Board of Directors. For more information, please visit www.sucampo.com.


News Articles [997 Associated News Articles listed on BioPortfolio]

Mallinckrodt to buy Sucampo Pharmaceuticals

Specialty pharmaceuticals manufacturer Mallinckrodt has agreed to buy biopharmaceuticals producer Sucampo, including its commercial and development assets.  The transaction is subject to customar...

Mallinckrodt to acquire Sucampo Pharmaceuticals

Mallinckrodt and Sucampo Pharmaceuticals announced an agreement in which Mallinckrodt will acquire Sucampo for approximately $1.2 billion.The transaction was approved by the boards of directors of bot...

Mallinckrodt snaps up Sucampo for $1.2bn

UK-based pharma Mallinckrodt is buying US biopharma Sucampo Pharmaceuticals for around $1.2 billion.

Mallinckrodt agrees to buy Sucampo Pharma for $1.2bn

Mallinckrodt has signed an agreement to purchase all outstanding shares of Sucampo Pharmaceuticals for around $1.2bn. Under the agreement, Mallinckrodt...Read More... The post Mallinckrodt agrees to b...

Mallinckrodt buys Sucampo

Mallinckrodt PLC agreed to pay $18 per share (an 8% premium) to acquire Sucampo Pharmaceuticals Inc., a public firm developing treatments for GI conditions and rare diseases. Including debt, the enter...

Troubled Mallinckrodt pays $1.2bn for Sucampo

Specialist pharma company Mallinckrodt announced on 26 December that it is to acquire Sucampo Pharmaceuticals for around $1.2 billion. The company’s management are clearly looking to bring cheer to...

Sucampo Pharmaceuticals (SCMP) Downgraded by Zacks Investment Research

According to Zacks, "Sucampo's pending acquisition by Mallinckrodt for $1.2 billion have raised investor concerns that the latter may be underpaying for the company. A sNDA for label expansion of ...

Sucampo Pharmaceuticals (SCMP) Downgraded by Zacks Investment Research to Hold

According to Zacks, "Sucampo's pending acquisition by Mallinckrodt for $1.2 billion have raised investor concerns that the latter may be underpaying for the company. A sNDA for label expansion of ...

Drugs and Medications [286 Associated Drugs and Medications listed on BioPortfolio]

Prevacid [Novartis Consumer Health, Inc.]

PREVACID 24 HRLansoprazole delayed-release capsules 15mg / acid reducer

Edarbi [Takeda Pharmaceuticals America, Inc.]

These HIGHLIGHTS do not include all the information needed to use EDARBI safely and effectively. See full prescribing information for EDARBI. Edarbi (azilsartan medoxomil) tabletsInitial U.S. Approval...

Lupron depot ped [Takeda Pharmaceutical Company LTD]

LUPRON DEPOT-PED (leuprolide acetate for depot suspension) 7.5 mg, 11.25 mg and 15 mg

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash

Actos [Takeda Pharmaceutical Co LTD]

ACTOS (pioglitazone hydrochloride) Tablets

PubMed Articles [141 Associated PubMed Articles listed on BioPortfolio]

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Ja...

Measurement of three-dimensional wavefronts using the Ichikawa-Lohmann-Takeda solution to the irradiance transport equation.

In this paper, we use the irradiance transport equation and the Fourier transform-based experimental solution given by Ichikawa-Lohmann-Takeda. We analyze experimental factors such as the digital filt...

Genetics of familial hypercholesterolemia: a tool for development of novel lipid lowering pharmaceuticals?

Familial hypercholesterolemia is characterized by high LDL cholesterol and an elevated risk to develop coronary heart disease. Mutations in LDL receptor-mediated cholesterol uptake are the main cause ...

Post-production handling and administration of protein pharmaceuticals and potential instability issues.

The safety and efficacy of protein pharmaceuticals depend not only on biological activity, but also on purity levels. Impurities may be process related due to limitations in manufacturing, or product ...

A General Strategy for Site-Selective Incorporation of Deuterium and Tritium into Pyridines, Diazines and Pharmaceuticals.

Methods to incorporate deuterium and tritium atoms into organic molecules are valuable for medicinal chemistry. The prevalence of pyridines and diazines in pharmaceuticals means that new ways to label...

Clinical Trials [221 Associated Clinical Trials listed on BioPortfolio]

A Bioequivalence Study of Dexlansoprazole From Doxirazole 60 mg Capsules (Hikma Pharma,Egypt)and Dexilant 60 mg Delayed Release (DR) Capsules (Takeda Pharmaceuticals America Inc., USA)

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Dexlansoprazole from Doxirazole 60 mg Capsules (Hikma Pharma,Egypt)and Dexilant...

Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants

The purpose of this study is to assess the bioavailability of dexlansoprazole from a 30 milligram (mg) or 60 mg delayed-release capsule manufactured at Takeda GmbH Plant Oranienburg, Germa...

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic®20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sep...

Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic 20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sepa...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Companies [1348 Associated Companies listed on BioPortfolio]

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc.

Sucampo Pharmaceuticals, Inc. is a global pharmaceutical company focused on innovative research, discovery, development and commercialization of proprietary drugs based on proston...

Sucampo Pharmaceuticals, Inc. and Takeda

Sucampo Pharmaceuticals, Inc., an international pharmaceutical company, is focused on the discovery, development and commercialization of proprietary drugs based on prostones. The...

Sucampo Pharmaceuticals, Inc. and Abbott

Sucampo Pharmaceuticals, Inc., an international biopharmaceutical company based in Bethesda, Maryland, focuses on the development and commercialization of medicines based on prost...

Sucampo Pharmaceuticals, Inc. and Numab AG

Sucampo Pharmaceuticals, Inc., an international pharmaceutical company based in Bethesda, Maryland, is focused on the discovery, development and commercialization of proprietary d...

Sucampo Pharmaceuticals, Inc.

About chronic idiopathic constipation

More Information about "Sucampo Pharmaceuticals, Inc. and Takeda" on BioPortfolio

We have published hundreds of Sucampo Pharmaceuticals, Inc. and Takeda news stories on BioPortfolio along with dozens of Sucampo Pharmaceuticals, Inc. and Takeda Clinical Trials and PubMed Articles about Sucampo Pharmaceuticals, Inc. and Takeda for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Sucampo Pharmaceuticals, Inc. and Takeda Companies in our database. You can also find out about relevant Sucampo Pharmaceuticals, Inc. and Takeda Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...


Corporate Database Quicklinks



Searches Linking to this Company Record